Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria

Natural killer (NK) cells are potent immune effectors that can be activated via antibody-mediated Fc receptor engagement. Using multiparameter flow cytometry, we found that NK cells degranulate and release IFN-γ upon stimulation with antibody-opsonized Plasmodium falciparum merozoites. Antibody-dependent NK (Ab-NK) activity was largely strain transcending and enhanced invasion inhibition into erythrocytes. Ab-NK was associated with the successful control of parasitemia after experimental malaria challenge in African adults. In an independent cohort study in children, Ab-NK increased with age, was boosted by concurrent P. falciparum infections, and was associated with a lower risk of clinical episodes of malaria. Nine of the 14 vaccine candidates tested induced Ab-NK, including some less well-characterized antigens: P41, P113, MSP11, RHOPH3, and Pf_11363200. These data highlight an important role of Ab-NK activity in immunity against malaria and provide a potential mechanism for evaluating vaccine candidates. Description Antibody-dependent natural killer cell activation is induced by merozoites and is associated with immunity against malaria. A different antibody angle Natural killer (NK) cells have been shown to mediate immune responses against Plasmodium falciparum using multiple effector functions. Odera et al. now show that antibody-opsonized P. falciparum merozoites can induce NK cell degranulation and IFN-γ production. This response was not strain specific and reduced invasion of merozoites into uninfected red blood cells. Using a controlled human malaria infection study in adults, they observed that antibody-dependent NK (Ab-NK) cell activity correlated directly with the control of parasitemia. In addition, in a cohort of children living in an endemic malaria setting, Ab-NK frequency increased with age, was boosted during P. falciparum infection, and was linked to a reduced risk of clinical malaria. These findings highlight a key role for antibody-mediated NK cell responses during malaria. —CF

[1]  Fergal J. Duffy,et al.  Systems analysis of immune responses to attenuated P. falciparum malaria sporozoite vaccination reveals excessive inflammatory signatures correlating with impaired immunity , 2021, bioRxiv.

[2]  P. Njuguna,et al.  Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection , 2021, JCI insight.

[3]  G. McFadden,et al.  Mechanisms and targets of Fcγ-receptor mediated immunity to malaria sporozoites , 2021, Nature Communications.

[4]  S. Kent,et al.  Antibody mediated activation of natural killer cells in malaria exposed pregnant women , 2021, Scientific reports.

[5]  D. Lauffenburger,et al.  Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination , 2020, Science Translational Medicine.

[6]  J. Bailey,et al.  A New Hope for CD56negCD16pos NK Cells as Unconventional Cytotoxic Mediators: An Adaptation to Chronic Diseases , 2020, Frontiers in Cellular and Infection Microbiology.

[7]  D. Baker,et al.  Differential IL-18 Dependence of Canonical and Adaptive NK Cells for Antibody Dependent Responses to P. falciparum , 2020, Frontiers in Immunology.

[8]  D. Campana,et al.  NK cells for cancer immunotherapy , 2020, Nature Reviews Drug Discovery.

[9]  Kwaku Poku Asante,et al.  Antibody Reactivity to Merozoite Antigens in Ghanaian Adults Correlates With Growth Inhibitory Activity Against Plasmodium falciparum in Culture , 2019, Open forum infectious diseases.

[10]  Peter D. Crompton,et al.  Adaptive NK cells in people exposed to Plasmodium falciparum correlate with protection from malaria , 2019, The Journal of experimental medicine.

[11]  Danny W. Wilson,et al.  Targets of complement-fixing antibodies in protective immunity against malaria in children , 2019, Nature Communications.

[12]  M. Good,et al.  Challenges and strategies for developing efficacious and long-lasting malaria vaccines , 2019, Science Translational Medicine.

[13]  G. Kamuyu,et al.  Serological Profiling for Malaria Surveillance Using a Standard ELISA Protocol. , 2019, Methods in molecular biology.

[14]  J. Rayner,et al.  KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization , 2018, Front. Immunol..

[15]  P. Njuguna,et al.  Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity , 2018, Wellcome open research.

[16]  P. Njuguna,et al.  Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity , 2018, Wellcome open research.

[17]  I. Wilson,et al.  A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA , 2018, Nature Communications.

[18]  Peter D. Crompton,et al.  NK cells inhibit Plasmodium falciparum growth in red blood cells via antibody-dependent cellular cytotoxicity , 2018, eLife.

[19]  G. Alter,et al.  Poorly cytotoxic terminally differentiated CD56negCD16pos NK cells accumulate in Kenyan children with Burkitt lymphomas. , 2018, Blood advances.

[20]  Peter D. Crompton,et al.  Synergistic malaria vaccine combinations identified by systematic antigen screening , 2017, Proceedings of the National Academy of Sciences.

[21]  J. Rayner,et al.  Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development , 2017, eLife.

[22]  D. Cooper,et al.  Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption , 2017, Journal of Virology.

[23]  I. Melero,et al.  Targeting NK-cell checkpoints for cancer immunotherapy. , 2017, Current opinion in immunology.

[24]  E. Riley,et al.  NK Cells: Uncertain Allies against Malaria , 2017, Front. Immunol..

[25]  K. Marsh,et al.  Cord blood IgG and the risk of severe Plasmodium falciparum malaria in the first year of life , 2017, International journal for parasitology.

[26]  R. Koup,et al.  HIV antibodies for treatment of HIV infection , 2017, Immunological reviews.

[27]  Shripad Tuljapurkar,et al.  Distinct genomic architecture of Plasmodium falciparum populations from South Asia. , 2016, Molecular and biochemical parasitology.

[28]  I. Barr,et al.  What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins , 2016, EBioMedicine.

[29]  H. Ljunggren,et al.  Emerging insights into natural killer cells in human peripheral tissues , 2016, Nature Reviews Immunology.

[30]  T. Horii,et al.  Recent advances in recombinant protein-based malaria vaccines , 2015, Vaccine.

[31]  T. Horii,et al.  Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort , 2015, Clinical and Vaccine Immunology.

[32]  Arlo Z. Randall,et al.  Plasmodium falciparum Protein Microarray Antibody Profiles Correlate With Protection From Symptomatic Malaria in Kenya. , 2015, The Journal of infectious diseases.

[33]  Susan Holmes,et al.  Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility , 2015, Science Translational Medicine.

[34]  S. C. T. P. Rts.  Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial , 2015, The Lancet.

[35]  D. Conway,et al.  Human Antibodies Fix Complement to Inhibit Plasmodium falciparum Invasion of Erythrocytes and Are Associated with Protection against Malaria , 2015, Immunity.

[36]  R. Fischer,et al.  Antimalarial Activity of Granzyme B and Its Targeted Delivery by a Granzyme B–Single-Chain Fv Fusion Protein , 2014, Antimicrobial Agents and Chemotherapy.

[37]  J. Rayner,et al.  New antigens for a multicomponent blood-stage malaria vaccine , 2014, Science Translational Medicine.

[38]  S. Kent,et al.  Influenza-Specific Antibody-Dependent Cellular Cytotoxicity: Toward a Universal Influenza Vaccine , 2014, The Journal of Immunology.

[39]  K. Marsh,et al.  Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria , 2014, BMC Medicine.

[40]  J. Dvorin,et al.  Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection , 2014, Science.

[41]  S. Draper,et al.  Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome , 2014, Journal of leukocyte biology.

[42]  K. Marsh,et al.  Breadth of anti-merozoite antibody responses is associated with the genetic diversity of asymptomatic Plasmodium falciparum infections and protection against clinical malaria. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  R. Coppel,et al.  Sequential Processing of Merozoite Surface Proteins during and after Erythrocyte Invasion by Plasmodium falciparum , 2013, Infection and Immunity.

[44]  K. Campbell,et al.  Natural killer cell biology: an update and future directions. , 2013, The Journal of allergy and clinical immunology.

[45]  B. Lowe,et al.  A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria☆ , 2013, Vaccine.

[46]  A. Cowman,et al.  Identification and Prioritization of Merozoite Antigens as Targets of Protective Human Immunity to Plasmodium falciparum Malaria for Vaccine and Biomarker Development , 2013, The Journal of Immunology.

[47]  Gilean McVean,et al.  Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia , 2013, Nature Genetics.

[48]  A. Hill,et al.  Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? , 2012, Human vaccines & immunotherapeutics.

[49]  Dominic P. Kwiatkowski,et al.  BASIGIN is a receptor essential for erythrocyte invasion by Plasmodium falciparum , 2011, Nature.

[50]  M. Caligiuri,et al.  Innate or Adaptive Immunity? The Example of Natural Killer Cells , 2011, Science.

[51]  Danny W. Wilson,et al.  Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development , 2010, Proceedings of the National Academy of Sciences.

[52]  Pierre Baldi,et al.  A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray , 2010, Proceedings of the National Academy of Sciences.

[53]  L. Marrama,et al.  Clinical Protection from Falciparum Malaria Correlates with Neutrophil Respiratory Bursts Induced by Merozoites Opsonized with Human Serum Antibodies , 2010, PloS one.

[54]  Jack S. Richards,et al.  The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis , 2010, PLoS medicine.

[55]  Achim Zeileis,et al.  Generalized Maximally Selected Statistics , 2008, Biometrics.

[56]  M. D'Ombrain,et al.  Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  D. Conway,et al.  Breadth and Magnitude of Antibody Responses to Multiple Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Clinical Malaria , 2008, Infection and Immunity.

[58]  A. Thomas,et al.  Apical membrane antigen 1: a malaria vaccine candidate in review. , 2008, Trends in parasitology.

[59]  B. Lowe,et al.  A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya , 2006, PLoS clinical trials.

[60]  K. Marsh,et al.  Immune effector mechanisms in malaria , 2006, Parasite immunology.

[61]  Eric O Long,et al.  Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. , 2006, Blood.

[62]  R. Snow,et al.  Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. , 2005, The Journal of infectious diseases.

[63]  T. Taylor,et al.  Intravenous immunoglobulin in the treatment of paediatric cerebral malaria , 1992, Clinical and experimental immunology.

[64]  D. Kemp,et al.  Subtelomeric chromosome deletions in field isolates of Plasmodium falciparum and their relationship to loss of cytoadherence in vitro. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[65]  I. McGregor,et al.  Gamma-Globulin and Acquired Immunity to Human Malaria , 1961, Nature.